HIKMA Pharmaceuticals yesterday said it expects full year performance to be closer to the top end of its guidance after its global vaccine products delivered strong growth.

Delivering a trading update yesterday, the London-based manufacturer projected full year generic pharmaceuticals revenue to be in the range of $810m (£600m) to $830m (£710.4m).

(c) 2021 City A.M., source Newspaper